Skip to Main Content
Beta test
our new site.
(
NLM Technical Bulletin
)
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
Study Results
Related Studies
Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer
This study has been completed.
Study NCT00005908 Information provided by National Institutes of Health Clinical Center (CC)
First Received on June 13, 2000. Last Updated on March 13, 2013
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Breast Cancer
Breast Neoplasm
Additional conditions recognized in this trial
Breast Neoplasms
Neoplasms
More general conditions related to this trial
Breast Diseases
Neoplasms by Site
Skin Diseases
Interventions listed in this trial
Docetaxel - Dose A
Anastrozole
cyclophosphamide
Docetaxel - Dose B
Doxorubicin hydrochloride
Tamoxifen Citrate
Capecitabine - Dose B
Capecitabine - Dose A
Additional drug interventions recognized in this trial
Capecitabine
Docetaxel
Doxorubicin
Fluorouracil
Tamoxifen
More general drug interventions related to this trial
Alkylating Agents
Antibiotics, Antineoplastic
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Antineoplastic Agents, Hormonal
Antirheumatic Agents
Aromatase Inhibitors
Bone Density Conservation Agents
Enzyme Inhibitors
Estrogen Antagonists
Estrogen Receptor Modulators
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Myeloablative Agonists
Pharmacologic Actions
Physiological Effects of Drugs
Selective Estrogen Receptor Modulators
Therapeutic Uses
Sponsors listed in this trial
National Cancer Institute (NCI)
Back to top of Main Content
